{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,5,26]],"date-time":"2024-05-26T23:40:14Z","timestamp":1716766814038},"reference-count":20,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,5,26]]},"DOI":"10.7759\/cureus.61137","type":"journal-article","created":{"date-parts":[[2024,5,26]],"date-time":"2024-05-26T23:21:25Z","timestamp":1716765685000},"source":"Crossref","is-referenced-by-count":0,"title":["Disseminated Cutaneous Mucormycosis Developing in Peristomal Pyoderma Gangrenosum"],"prefix":"10.7759","author":[{"given":"David A","family":"Prentice","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erasmia","family":"Christou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wendy  A","family":"Pearson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1093\/mmy\/myx101","article-title":"Challenges in the diagnosis and treatment of mucormycosis","volume":"56","author":"Skiada A","year":"2018","unstructured":"Skiada A, Lass-Floerl C, Klimko N, Ibrahim A, Roilides E, Petrikkos G. Challenges in the diagnosis and treatment of mucormycosis. Med Mycol. 2018, 56:93-101. 10.1093\/mmy\/myx101","journal-title":"Med Mycol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1111\/iwj.13164","article-title":"A novel topical therapy for resistant and early peristomal pyoderma gangrenosum","volume":"16","author":"Pearson WA","year":"2019","unstructured":"Pearson WA, Prentice DA, Sinclair DL, Lim LY, Carville KJ. A novel topical therapy for resistant and early peristomal pyoderma gangrenosum. Int Wound J. 2019, 16:1136-43. 10.1111\/iwj.13164","journal-title":"Int Wound J"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-4632.2004.02128.x","article-title":"Pyoderma gangrenosum: clinicopathologic correlation and proposed diagnostic criteria","volume":"43","author":"Su WP","year":"2004","unstructured":"Su WP, Davis MD, Weenig RH, Powell FC, Perry HO. Pyoderma gangrenosum: clinicopathologic correlation and proposed diagnostic criteria. Int J Dermatol. 2004, 43:790-800. 10.1111\/j.1365-4632.2004.02128.x","journal-title":"Int J Dermatol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2017.5980","article-title":"Diagnostic criteria of ulcerative pyoderma gangrenosum: a Delphi consensus of international experts","volume":"154","author":"Maverakis E","year":"2018","unstructured":"Maverakis E, Ma C, Shinkai K, et al.. Diagnostic criteria of ulcerative pyoderma gangrenosum: a Delphi consensus of international experts. JAMA Dermatol. 2018, 154:461-6. 10.1001\/jamadermatol.2017.5980","journal-title":"JAMA Dermatol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/461467","article-title":"Pyoderma gangrenosum: a review of clinical features and outcomes of 23 cases requiring inpatient management","volume":"2014","author":"Ye MJ","year":"2014","unstructured":"Ye MJ, Ye JM. Pyoderma gangrenosum: a review of clinical features and outcomes of 23 cases requiring inpatient management. Dermatol Res Pract. 2014, 2014:461467. 10.1155\/2014\/461467","journal-title":"Dermatol Res Pract"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2011.10565.x","article-title":"Pyoderma gangrenosum: a retrospective review of patient characteristics, comorbidities and therapy in 103 patients","volume":"165","author":"Binus AM","year":"2011","unstructured":"Binus AM, Qureshi AA, Li VW, Winterfield LS. Pyoderma gangrenosum: a retrospective review of patient characteristics, comorbidities and therapy in 103 patients. Br J Dermatol. 2011, 165:1244-50. 10.1111\/j.1365-2133.2011.10565.x","journal-title":"Br J Dermatol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.5070\/D329260775","article-title":"Cutaneous mucormycosis involving a colostomy site","volume":"29","author":"Akram MR","year":"2023","unstructured":"Akram MR, Miller S, Vandergriff T. Cutaneous mucormycosis involving a colostomy site. Dermatol Online J. 2023, 29:10.5070\/D329260775","journal-title":"Dermatol Online J"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1097\/00152192-199911000-00008","article-title":"Severe peristomal pyoderma gangrenosum: a case study","volume":"26","author":"Brady E","year":"1999","unstructured":"Brady E. Severe peristomal pyoderma gangrenosum: a case study. J Wound Ostomy Cont. 1999, 26:306-11. 10.1097\/00152192-199911000-00008","journal-title":"J Wound Ostomy Cont"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2017.04.014","article-title":"Black stoma: what could it be?","volume":"153","author":"Hashash JG","year":"2017","unstructured":"Hashash JG, Minervini M, Cruz RJ Jr. Black stoma: what could it be?. Gastroenterology. 2017, 153:e12-3. 10.1053\/j.gastro.2017.04.014","journal-title":"Gastroenterology"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cir865","article-title":"Pathogenesis of mucormycosis","volume":"54 Suppl 1","author":"Ibrahim AS","year":"2012","unstructured":"Ibrahim AS, Spellberg B, Walsh TJ, Kontoyiannis DP. Pathogenesis of mucormycosis. Clin Infect Dis. 2012, 54 Suppl 1:S16-22. 10.1093\/cid\/cir865","journal-title":"Clin Infect Dis"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.18.3.556-569.2005","article-title":"Novel perspectives on mucormycosis: pathophysiology, presentation, and management","volume":"18","author":"Spellberg B","year":"2005","unstructured":"Spellberg B, Edwards J Jr, Ibrahim A. Novel perspectives on mucormycosis: pathophysiology, presentation, and management. Clin Microbiol Rev. 2005, 18:556-69. 10.1128\/CMR.18.3.556-569.2005","journal-title":"Clin Microbiol Rev"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11133620","article-title":"Current treatment options for COVID-19 associated mucormycosis: present status and future perspectives","volume":"11","author":"Madhavan Y","year":"2022","unstructured":"Madhavan Y, Sai KV, Shanmugam DK, et al.. Current treatment options for COVID-19 associated mucormycosis: present status and future perspectives. J Clin Med. 2022, 11:10.3390\/jcm11133620","journal-title":"J Clin Med"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.3390\/jof8020194","article-title":"Global cutaneous mucormycosis: a systematic review","volume":"8","author":"Skiada A","year":"2022","unstructured":"Skiada A, Drogari-Apiranthitou M, Pavleas I, Daikou E, Petrikkos G. Global cutaneous mucormycosis: a systematic review. J Fungi (Basel). 2022, 8:10.3390\/jof8020194","journal-title":"J Fungi (Basel)"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cir868","article-title":"Early clinical and laboratory diagnosis of invasive pulmonary, extrapulmonary, and disseminated mucormycosis (zygomycosis)","volume":"54 Suppl 1","author":"Walsh TJ","year":"2012","unstructured":"Walsh TJ, Gamaletsou MN, McGinnis MR, Hayden RT, Kontoyiannis DP. Early clinical and laboratory diagnosis of invasive pulmonary, extrapulmonary, and disseminated mucormycosis (zygomycosis). Clin Infect Dis. 2012, 54 Suppl 1:S55-60. 10.1093\/cid\/cir868","journal-title":"Clin Infect Dis"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.3390\/jof5010024","article-title":"Molecular strategies to diagnose mucormycosis","volume":"5","author":"Millon L","year":"2019","unstructured":"Millon L, Scherer E, Rocchi S, Bellanger AP.  Molecular strategies to diagnose mucormycosis. J Fungi (Basel). 2019, 5:10.3390\/jof5010024","journal-title":"J Fungi (Basel)"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1007\/s12281-023-00456-2","article-title":"The impact of corticosteroids on the outcome of fungal disease: a systematic review and meta-analysis","volume":"17","author":"Li Z","year":"2023","unstructured":"Li Z, Denning DW. The impact of corticosteroids on the outcome of fungal disease: a systematic review and meta-analysis. Curr Fungal Infect Rep. 2023, 17:54-70. 10.1007\/s12281-023-00456-2","journal-title":"Curr Fungal Infect Rep"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1080\/21505594.2015.1039762","article-title":"Glucocorticosteroids do not impact directly growth rate and biomass of Rhizopus arrhizus (syn. R. oryzae) in vitro","volume":"6","author":"Bellanger AP","year":"2015","unstructured":"Bellanger AP, Minetos YD, Albert N, Shirazi F, Walsh TJ, Kontoyiannis DP. Glucocorticosteroids do not impact directly growth rate and biomass of Rhizopus arrhizus (syn. R. oryzae) in vitro. Virulence. 2015, 6:441-3. 10.1080\/21505594.2015.1039762","journal-title":"Virulence"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01366-15","article-title":"pH manipulation as a novel strategy for treating mucormycosis","volume":"59","author":"Trzaska WJ","year":"2015","unstructured":"Trzaska WJ, Correia JN, Villegas MT, May RC, Voelz K. pH manipulation as a novel strategy for treating mucormycosis. Antimicrob Agents Chemother. 2015, 59:6968-74. 10.1128\/AAC.01366-15","journal-title":"Antimicrob Agents Chemother"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.3390\/jof5030069","article-title":"A guide to investigating suspected outbreaks of mucormycosis in healthcare","volume":"5","author":"Hartnett KP","year":"2019","unstructured":"Hartnett KP, Jackson BR, Perkins KM, et al.. A guide to investigating suspected outbreaks of mucormycosis in healthcare. J Fungi (Basel). 2019, 5:10.3390\/jof5030069","journal-title":"J Fungi (Basel)"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cir867","article-title":"Healthcare-associated mucormycosis","volume":"54 Suppl 1","author":"Rammaert B","year":"2012","unstructured":"Rammaert B, Lanternier F, Zahar JR, Dannaoui E, Bougnoux ME, Lecuit M, Lortholary O. Healthcare-associated mucormycosis. Clin Infect Dis. 2012, 54 Suppl 1:S44-54. 10.1093\/cid\/cir867","journal-title":"Clin Infect Dis"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/247982-disseminated-cutaneous-mucormycosis-developing-in-peristomal-pyoderma-gangrenosum","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,26]],"date-time":"2024-05-26T23:21:27Z","timestamp":1716765687000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/247982-disseminated-cutaneous-mucormycosis-developing-in-peristomal-pyoderma-gangrenosum"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,26]]},"references-count":20,"URL":"https:\/\/doi.org\/10.7759\/cureus.61137","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,5,26]]}}}